Stock RNAZ TRANSCODE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Real-time Estimate Cboe BZX
Other stock markets
 10:11:04 2024-07-11 am EDT 		5-day change 1st Jan Change
0.929 USD +3.22% Intraday chart for TransCode Therapeutics, Inc. +21.04% -86.04%
May. 29 TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 CI
May. 15 TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
AQ
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
AQ
TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
CI
TransCode Therapeutics : Investor Presentation
PU
TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
TransCode Therapeutics Open Letter to Shareholders
AQ
TransCode Therapeutics : Shareholder Meeting - Form 8-K
PU
Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.
CI
Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.
CI
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.
CI
TransCode Therapeutics Cleared by FDA for Phase 1/2 Trial of TTX-MC138 for Advanced Solid Tumors
MT
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
AQ
TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors
CI
TransCode Therapeutics Reports 2023 Results; Provides Business Update
AQ
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
AQ
TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
CI
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
AQ
TransCode Therapeutics, Inc. and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
CI
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RNAZ Stock
  4. News TransCode Therapeutics, Inc.